{'52WeekChange': 0.8434268,
 'SandP52WeekChange': None,
 'address1': '7000 Shoreline Court',
 'address2': 'Suite 350',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 11.9,
 'askSize': 1000,
 'averageDailyVolume10Day': 184212,
 'averageVolume': 288906,
 'averageVolume10days': 184212,
 'beta': None,
 'beta3Year': None,
 'bid': 11.86,
 'bidSize': 1800,
 'bookValue': 4.382,
 'category': None,
 'circulatingSupply': None,
 'city': 'South San Francisco',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 12.65,
 'dayLow': 11.79,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -3.554,
 'enterpriseToRevenue': None,
 'enterpriseValue': 161213888,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 12.764428,
 'fiftyTwoWeekHigh': 19.97,
 'fiftyTwoWeekLow': 2.95,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 7645751,
 'forwardEps': -1.63,
 'forwardPE': -7.3006134,
 'fromCurrency': None,
 'fullTimeEmployees': 43,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0.26033002,
 'heldPercentInstitutions': 0.52744,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/ideayabio.com',
 'longBusinessSummary': 'IDEAYA Biosciences, Inc., an oncology-focused '
                        'precision medicine company, focuses on the discovery '
                        'and development of targeted therapeutics for patient '
                        'populations selected using molecular diagnostics. The '
                        "company's product candidate is IDE196, a protein "
                        'kinase C inhibitor that is in Phase 1/2 clinical '
                        'trial for genetically-defined cancers having GNAQ or '
                        'GNA11 gene mutations. Its preclinical pipeline '
                        'includes various synthetic lethality programs '
                        'targeting MAT2A for solid tumors with MTAP deletions; '
                        'Pol-theta in tumors with homologous recombination '
                        'deficiency, including BRCA mutations; PARG in tumors '
                        'with BRCA2 mutations in base excision repair; and WRN '
                        'in high microsatellite instability tumors. The '
                        'company has a research collaboration agreement with '
                        'Cancer Research UK and the University of Manchester '
                        'to develop small molecule inhibitors of Poly '
                        '(ADP-ribose) glycohydrolase; and a clinical trial '
                        'collaboration and supply agreement with Pfizer Inc. '
                        'for Phase 1/2 study in metastatic uveal melanoma and '
                        'other solid tumors, as well as a strategic '
                        'partnership with GlaxoSmithKline plc. IDEAYA '
                        'Biosciences, Inc. was founded in 2015 and is '
                        'headquartered in South San Francisco, California.',
 'longName': 'IDEAYA Biosciences, Inc.',
 'market': 'us_market',
 'marketCap': 322087776,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_329719147',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -44449000,
 'nextFiscalYearEnd': 1640908800,
 'open': 12.43,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '650 443 6209',
 'previousClose': 12.48,
 'priceHint': 2,
 'priceToBook': 2.7156549,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 12.65,
 'regularMarketDayLow': 11.79,
 'regularMarketOpen': 12.43,
 'regularMarketPreviousClose': 12.48,
 'regularMarketPrice': 12.43,
 'regularMarketVolume': 125942,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 27066200,
 'sharesPercentSharesOut': 0.0612,
 'sharesShort': 1657600,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 223119,
 'shortName': 'IDEAYA Biosciences, Inc.',
 'shortPercentOfFloat': 0.0958,
 'shortRatio': 2.88,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'IDYA',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.572,
 'twoHundredDayAverage': 8.181007,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '5a0bbfba-0289-3587-8e76-6a2418bad8f3',
 'volume': 125942,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.ideayabio.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '94080'}